HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
Division of Endocrinology and Diabetes Research Studies
1 - 10 of 30
Beta-cell Responsiveness to the Incretin Hormones (Aim1)
The goal of the study extension is to see whether the incretin hormone GIP increases insulin secretion in individuals with CF and normal glucose tolerance compared to individuals without CF and normal glucose tolerance.
Blood Sugar Stability in Individuals with Hyperinsulinism
The purpose of the study is to evaluate blood sugar levels and beta-cell function in adolescents and adult with KATP hyperinsulinism whom did not undergo pancreatectomy.
Canagliflozin in Children with Type 2 Diabetes
The goal of this study is to investigate the efficacy and safety of Canagliflozin (which is experimental) in children and adolescents ages 10 to 18 years old with Type 2 diabetes and poor control (i.e., an HbA1c of 6.5% to 10.5%).
The Child and Adolescent Thyroid Consortium (CATC) Biorepository is a collaborative research program dedicated to studying thyroid cancers and other thyroid-related conditions.
Characterization of Insulin and Incretin Secretion in Postpubertal Adolescents and Adults with Cystic Fibrosis~A Pilot Study
The purpose of this research study is to examine and understand the various mechanisms that contribute to CFRD and gain a better understanding of potential means to treat CFRD.
Chronic Incretin-based therapy in Cystic Fibrosis (Aim 2)
The purpose of this research study is to examine and understand the various mechanisms that contribute to Cystic Fibrosis Related Diabetes and gain a better understanding of potential means to treat Cystic Fibrosis Related Diabetes.
Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism
This study is a 2 period, open label study that will evaluate the safety and efficacy of dasiglucagon in children between the ages of 3 months and 12 years.
Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism (for children under 1 year of age)
This study is a randomized, double-blind, placebo-controlled study that will evaluate the safety and efficacy of dasiglucagon in children between the ages of 7 days and 12 months who have congenital hyperinsulinism.
Designing the ThyTSQ for Teens and Parents
This study aims to design and optimize the Hypothyroidism Treatment Satisfaction Questionnaire (ThyTSQ) for measuring treatment satisfaction.
DTX401 Gene Therapy in Glycogen Storage Disease (GSD) Type Ia
Our team at the Congenital Hyperinsulinism Center at CHOP is working on a research study to determine whether an experimental gene therapy product, DTX401, is safe and effective in people with glycogen storage disease type Ia (GSDIa)